Genmab (GMAB) EGM 2026 presentation summary
Event summary combining transcript, slides, and related documents.
EGM 2026 presentation summary
9 Oct, 2026EGM agenda
Agenda covered the Board of Directors’ proposal and any other business.
Proposed 2026 board remuneration
Annual base cash fee: DKK 600,000 for a Board member; Chair fee 2.0x and Deputy Chair fee 1.5x the base fee.
RSU value: Chair 3.0x and Deputy Chair and Board members 2.5x the fixed annual base fee, under the Remuneration Policy.
Annual committee fees: Audit and Finance DKK 150,000 for Chair and DKK 100,000 for members; Compensation DKK 120,000 and DKK 80,000, respectively.
Annual committee fees: Nominating and Corporate Governance DKK 100,000 for Chair and DKK 70,000 for members; Scientific DKK 130,000 and DKK 100,000, respectively.
Committee meeting fee: DKK 10,000 per meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genmab
- AbbVie collaboration pairs three bispecific programs with up to four discovery candidates.GMAB
Collaboration - Pivotal phase III oncology readouts in Q4 2026 set up three major launches in 2027.GMAB
Bank of America Global Healthcare Conference - Late-stage pipeline advances and strong growth set up major Q4 data readouts in oncology.GMAB
Morgan Stanley 24th Annual Global Healthcare Conference - Three key phase III oncology readouts are imminent, targeting major commercial opportunities.GMAB
Wells Fargo 21st Annual Healthcare Conference - Raised 2026 revenue guidance and late-stage pipeline set up multiple 2027 launches.GMAB
Investor presentation - Revenue up 25% to $2.05B; profit up, net down on costs; 2026 outlook raised.GMAB
Q2 2026 - 29% revenue growth, raised guidance, and ProfoundBio acquisition highlight strong momentum.GMAB
Q3 2024 - Promising efficacy and safety data drive phase III initiations for key pipeline assets.GMAB
Status Update - Rina-S® showed durable activity in gynecologic cancers, advancing toward Phase 3.GMAB
R&D Update